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RESUMO 
A síndrome cardiorenal caracteriza-se pela coexistência de doença cardíaca e renal num 
mesmo indivíduo, podendo afetar cães e gatos. A definição mais consensual descreve-o como um 
“distúrbio fisiopatológico do coração e dos rins, em que a afeção aguda ou crónica de um dos órgãos, 
origina dano agudo ou crónico no outro”.  
O interesse e reconhecimento da importância e prevalência desta síndrome em medicina 
veterinária tem sido crescente e, recentemente, um comité formado por médicos veterinários 
especialistas em cardiologia e nefrologia propuseram que a síndrome cardiorenal fosse designada 
como um distúrbio do eixo cardiovascular-renal, classificando-a em três tipos, consoante a origem do 
distúrbio: CvRDH para o coração como órgão de falência primário, CvRDK para rins como órgãos de 
falência primário e CvRDO para quando é originada por outras causas.  
A terapêutica atual para a síndrome cardiorenal é muito variada, e depende em muito da 
preferência do médico veterinário quanto aos fármacos utilizados. No entanto, há certas premissas que 
devem ser consideradas no que diz respeito a este desafio terapêutico e que não devem ser 
subvalorizadas, pois refletem-se seriamente no sucesso da terapêutica e consequentemente na 
esperança de vida do animal. As dosagens dos fármacos utilizados devem sofrer uma revisão 
constante, acompanhada de uma cuidada monitorização das funções cardíaca e renal do paciente, 
dado que o principal desafio reside na tentativa de melhorar ao máximo a função de um dos órgãos 
sem causar dano, ou deterioração, à função do outro.  
Esta dissertação tem como objetivo uma revisão do estado atual do conhecimento sobre a 
síndrome cardiorenal em animais de companhia, incidindo no seu diagnóstico, classificação e desafios 
terapêuticos. 
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ABSTRACT 
Cardiorenal syndrome is described by the coexistence of cardiac and renal disease on the 
same individual, and it can affect both dogs and cats. The most consensual definition describes it as a 
“pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of one of the 
organs causes acute or chronic dysfunction of the other”. 
The interest, recognition of the importance and prevailing of this syndrome in veterinary 
medicine has grown and, recently, a committee of veterinarians specialized in cardiology and 
nephrology proposed that cardiorenal syndrome would be further designated as cardiovascular-renal 
axis disorders, classifying it  in three types according to the disorders primary cause: CvRDH to heart as 
the primary failing organ, CvRDK to kidneys as the primary failing organ and CvRDO to when it has other 
causes. 
The current therapeutic for cardiorenal syndrome presents many variations, depending on the 
veterinarian preference as for what drugs should be used. However, there are certain assumptions that 
must be considered regarding this therapeutic challenge, and shouldn’t be undervalued since they take 
serious effect on the therapeutics success and, therefore, on the animal life expectancy. The dosages 
for the drugs used must suffer constant review, together with careful monitoring to the patients cardiac 
and renal functions, since the main challenge relies on the attempt to improve at the most one the organs 
function, without causing damage, or deterioration, to the other.  
This dissertation objective is to revise the current state of knowledge of cardiorenal syndrome 
in small animals, focusing on its diagnosis, classification and therapeutic challenge. 
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1. INTRODUCTION 
Cardiorenal syndrome (CRS) is a complex pathology that affects both the heart and kidneys, 
and it’s commonly seen in dogs and cats suffering from cardiac disorders. Although being one of the 
major setbacks to congestive heart failure (CHF) therapy, it’s not completely understood at this point, 
and by what reason, its definition hasn’t been set by the scientific community. It can, however, be roughly 
defined as a “pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction 
of one of the organs may induce acute or chronic dysfunction of the other” (Ronco et al., 2008).  
Despite the numerous possible causes for this syndrome, one of the most common 
presentations is renal decay due to heart failure. The heart function is to pump blood to all body tissues, 
and the renal system receives about 20-25% of the cardiac output, so it’s easy to infer that when a 
disease affects the heart, it will ultimately end up taking its toll on the kidneys as well. Renal function is, 
on the other hand, absolutely crucial to the organism, since, amongst other functions, it plays an 
essential role in osmoregulation and maintenance of blood pressure levels, which is of utmost 
importance when it comes to heart failure (HF) therapeutics.  
It’s common to have heart and kidney dysfunctions occurring simultaneously, since they share 
many of their causes and pathophysiologic mechanisms. Adding up to this, CHF therapies focus on 
improving myocardia function as well as achieving hemodynamic balance, but have harmful 
consequences to renal function (Aronson, 2012). 
 Renal deficits are now recognized as an independent risk factor when it comes to mortality 
and morbidity in patients suffering from HF. The mechanisms by which renal failure (RF) causes HF to 
deteriorate are not fully understood and there are several factors that contribute to the “heart/kidney 
vicious circle” (Palazzuoli & Ronco, 2011). 
About 10% of the dogs seen in veterinary practices are affected by some form of heart disease 
(C. Atkins et al., 2009), and that number grows to 75% in dogs over 16 years (Guglielmini, 2003). With 
the advances in HF therapeutics, we are able to delay disease progression, and death by the primary 
cause is becoming more uncommon in cardiac patients. 
With cardiopathic patients increased life expectancy, it’s important to turn our attention to the 
possible side effects from continuous cardiac therapy, such as CRS. Up to this point, the veterinary 
community hasn’t paid much attention to the important role that this pathology represents. In 2015, it 
was the first time that a group of veterinary cardiologists and nephrologists addressed this question, 
forming a consensus group, in order to achieve consensus around the definition, pathophysiology, 
diagnosis and management of cardiovascular-renal axis disorders (CvRD) (Pouchelon et al., 2015).   
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2. CARDIORENAL SYNDROME 
2.1. Definition 
CRS has yet to be fully defined. Many definitions have been placed throughout the years, but 
have failed to properly describe the fine interactions between heart and kidney and do not address all 
the leading key points of cardiorenal interface: which is the primary organ to fail; the “unidirectional or 
bidirectional” character of the interaction; the disease that causes organ failure; the pathophysiological 
mechanism behind the affection and ultimately the acute or chronical development of the process  
(Braam et al., 2013).  
First it was described as the common presentation of combined heart and kidney dysfunction 
(Shlipak & Massie, 2004). Then it was considered to be the existence or development of kidney damage 
due to heart failure (Heywood, 2005), and later a pathophysiological disorder where acute or chronical 
failure in one of the organs may cause acute or chronical damage to the other (Ronco et al., 2008). Most 
recently it was suggested that each failing organ has the capability to start and maintain disease in the 
other organ by feedback mechanisms, biochemical, immunological, neurohormonal and/or 
hemodynamic (Bock & Gottlieb, 2010b).  
Although many of the suggested definitions include some of the key points, none has been 
able grasp all of them, the classification suggested by Ronco, in 2008, in the most clinically appealing 
(Braam et al., 2013).  
2.2. Classification  
Ronco suggested a five-point classification for CRS. 
Table 1 - CRS classification. Adapted from Ronco et al. 2008 
CRS 
Type 1 
Acute CRS 
 Acute worsening of cardiac function causes acute kidney injury 
CRS 
Type 2  
Chronic CRS 
 
Chronical injuries to cardiac performance results in active damage to the kidney, 
resulting in chronic kidney disease 
CRS 
Type 3 
Acute renocardiac syndrome 
 Acute cardiac dysfunction outcomes of sudden RF 
CRS 
Type 4  
Chronic renocardiac syndrome  
 Chronic kidney disease leads to cardiac function decline and structural changes  
CRS 
Type 5 
Secondary CRS 
 
Acute or chronic systemic disorder causes combined worsening to renal and cardiac 
function 
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2.3. Cardiovascular-renal axis disorder  
All of the definitions and classifications above were elaborated by the medical community. 
With the purpose of formally define and describe this pathology in veterinary patients, a CRS Consensus 
Group of veterinarian cardiologists and nephrologists was formed in 2015. 
This entity proposed that CRS would be treated as “cardiovascular-renal disorders” in dogs 
and cats, in order to include the vasculature as an important piece, and since it can have many clinical 
presentations, with individual and breed variations, cannot be described as a single clinical syndrome 
(Pouchelon et al., 2015). 
CvRD are defined as “a disease, toxin or drug-induced structural and/or functional damage to 
the kidney and/or cardiovascular system, leading to disruption of the normal interactions between these 
systems, to the ongoing detriment of one or both” (Pouchelon et al., 2015) 
A classification into three different subgroups was also established based on the primary failing 
organ: CvRDH when a renal dysfunction occurs resulting from a disease concerning the cardiovascular 
system; CvRDK cardiovascular impairment caused by kidney disease and CvRDO describing damage to 
heart and kidneys simultaneously, due to concomitant primary disease in heart and kidneys or other 
pathologies, toxins, toxics or drugs that affects both systems.  
2.4. Pathophysiology 
The pathophysiology for CRS is not completely understood (Liang et al., 2006). The 
pathophysiologic mechanisms responsible for this syndrome are mainly due to hemodynamic 
alterations, such as, reduced renal pressure, increase to venous pressure, as well as the activation of 
various neurohormonal systems (Liang et al., 2006). Most of them are caused by compensatory 
mechanisms to HF, that end up contributing to worsen cardiac and renal function and at the end, lead 
to CRS (Liu et al., 2012). 
A diminished cardiac output, caused by cardiac function alteration in CHF, will result in lower 
blood flow and renal hypoperfusion. Baroreceptors are triggered, initiating renal vasoconstriction, 
activating the sympathetic nervous systems (SNS), and releasing catecholaminergic hormones. Fluid 
retention occurs, since SNS activation will increase renal vasoconstriction (Bock and Gottlieb 2010).  
Renal ischemia, oxidative stress, hypoxia and intrinsic renal diseases often activate renal 
sensory afferent signaling to hypothalamus, which combined with elevated central sympathetic tone are 
related with the development of CRS (DiBona, 2005; Sobotka et al., 2011).  
Patients with chronic kidney disease (CKD), are also more prone to develop CRS, resultant 
from oxidative stress, since the anti-oxidants and reactive oxygen species (ROS) that are formed 
stimulate inflammatory cytokines production (Galle, 2001). Migrating monocytes, neutrophils and 
macrophages will affect the myocardium, causing cardiac injury (Liu et al., 2012).  
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The renin-angiotensin-aldosterone system (RAAS) also plays an important role in CRS 
development. RAAS activation due to CHF or CKD will cause endothelial dysfunction, inhibition of the 
fibrinolytic system and also development of atherosclerosis. There is also an increase to blood pressure 
caused by angiotensin II, which will promote aldosterone secretion, triggering increased sodium and 
water reabsorption, and cause damage to heart and kidneys as a circulating hormone (Brewster & 
Perazella, 2004). 
Although there aren’t specific studies that correlate CRS pathophysiology to CvRD, empiric 
evidence and literature suggest the existence of similar patterns, such as neurohormonal activation, 
ROS and most of all, the intricate sequence of hemodynamic changes (Pouchelon et al., 2015).  
 
Figure 1 - Postulated mechanisms underlying the relationship between heart failure (HF) and renal 
dysfunction. Blue arrows indicate pathways by which HF may lead to RF. Red arrows indicate pathways 
by which RF may lead to HF. The relative importance of these mechanisms (and additional mechanisms 
not discussed) is not known (i.e. boxes are not drawn to scale). From (Pouchelon et al., 2015) 
2.4.1 Cardiovascular-renal axis disorders - Heart 
The indirect evidence to CvRDH in dogs and cats, resides on the renal function decrease in 
severe cardiac disease (Pouchelon et al., 2015), shown by presence of azotemia in 50% of dogs with 
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chronic valvular heart disease and 70% in those with a disease more severe (Nicolle et al., 2007). In 
cats with hypertrophic cardiomyopathy azotemia was found in 59% of the animals (Gouni et al., 2008). 
Potential etiologies to the development of this disorder are: systemic hypertension (SHT), 
cardiogenic shock, low cardiac output, systemic hypotension, systemic arterial thromboembolism, 
heartworm infection and passive kidney congestion (Pouchelon et al., 2015).  
Mechanisms that are considered to be responsible to cause kidney injure as a result from a 
cardiovascular disease involve the activation of RAAS and SNS, there’s also a reduction in kidney 
perfusion resultant from diminished cardiac output, kidneys venous congestion and formation of ROS 
due to injured endothelial tissue (Haase et al., 2013; McCullough et al., 2013). Treatment for CHF can 
also cause kidney disease due to exposure to diuretics and angiotensin converting enzyme inhibitors 
(ACEI), known to be potentially nephrotoxic drugs and to activate the RAAS, leading to volume 
depletion, vasoconstriction and diminished glomerular filtration rate (GFR), affecting renal function  
(Francis et al., 1990; Lantis et al., 2011; Pouchelon et al., 2015). 
2.4.2 Cardiovascular-renal axis disorders - Kidney 
Although being less common, primary disease involving the kidney such as kidney-mediated 
SHT, volume overload, hypokalemia or hyperkalemia, reduced renal clearance or drugs, uremic 
hypodipsia, uremic pericarditis, activation of RAAS and anemia caused by CKD, can lead to 
cardiovascular dysfunction (Pouchelon et al., 2015).  
Drugs such as enalapril, atenolol and digoxin, used for cardiac disease treatment, undertake 
renal excretion, causing primary kidney dysfunction, which leads to lower drug clearance and therefore 
sings of toxicity, like hypotension and arrhythmias, that will result in deteriorating myocardial function 
(Pouchelon et al., 2015). Patients with kidney disease present abnormal hemodynamic status and fluid 
volume  which can cause congestion resulting from systemic volume overload, mainly in animals 
suffering from cardiac disease (Much & Wilcox, 1982; Polzin, 2011). 
A common side effect to CKD is SHT that can cause dysfunction and hypertrophy in the 
myocardium of dogs and cats (Carlos Sampedrano et al., 2006; Chetboul et al., 2003; Henik et al., 2004) 
2.4.3 Cardiovascular-renal axis disorders - Others 
Despite of shortage of published evidence of CvRDO in dogs and cats, it’s considered that 
pathologies such as septic or neoplastic emboli, gastric dilation and volvus, infectious diseases, 
glycogen storage disease and amyloidosis, can lead, through various mechanisms, to kidney and 
cardiovascular impairment (Pouchelon et al., 2015). 
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2.5. Clinical assessment  
Early diagnosis of CRS, is essential when it comes to preventing disease progression. A close 
monitoring to renal activity parameters in cardiac patients, as well as heart function monitoring when 
there is evidence of acute kidney injury (AKI) or chronic kidney injury (CKI) are crucial.  
In order to obtain essential information for diagnosis it’s vital to perform a detailed anamnesis 
and physical examination, being attentive to certain symptoms that can indicate renal impairment, such 
as polyuria and polydipsia, or cardiac malfunction, as coughing, exercise intolerance, dyspnea and 
syncope, that can point to what further testing must be done, such as radiographic and ultrasonographic 
imaging, blood and urine testing and assessment of blood pressure (Pouchelon et al., 2015).  
A useful tool in monitoring is biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-
proBNP), B-type natriuretic peptide (BNP), N-terminal pro-atrial natriuretic peptide (NT-proANP) and 
cardiac troponin I (cTnI), the most common biomarkers used to assess cardiac function. Biomarkers are 
“a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” (Biomarkers 
Definitions Working Group, 2001). 
2.5.1. Renal function assessment 
When it comes to evaluate renal function there are many parameters that need to be taken 
account, which can be appraised using traditional urine and blood tests. For instance, GFR can be 
expressed by serum creatinine levels, glomerular permselectivity by serum or urine albumin and total 
protein concentration, proximal tube function by urine glucose and amino acid concentrations, ability to 
maintain electrolyte and acid-base balance by serum electrolytes and bicarbonate concentrations, and 
renal concentrating ability by urine specific gravity (Pouchelon et al., 2015). 
We can also resort to imaging to detect morphological abnormalities (Pouchelon et al., 2015). 
Information on kidney size, position, shape, unilateral or bilateral abnormalities and presence of 
radiosense uroliths can be obtained through a ventrodorsal abdominal radiography (Bartges, 2012; 
Polzin, 2011; Rivers & Johnston, 1996). Using echography we can evaluate integrity of structures as 
renal parenchyma, renal pelvis and urethra, as well as the presence of mineralization, uroliths, cysts, 
infarcts and abnormalities or renal blood flow (Debruyn et al., 2012; Lamb, 1998; Rivers & Johnston, 
1996). 
It’s also important to establish a stage to AKI and CKI, using International Renal Interest 
Society (IRIS) classification system. The IRIS system stages AKI based on creatinine concentration, 
unexpected glycosuria and cylindruria or abrupt inability to concentrate urine, and stages CKI based on 
serum creatinine and proteinuria (Pouchelon et al., 2015). 
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Table 2 - International Renal Interest Society grading criteria for AKI in dogs and cats. From 
(International Renal Interest Society, 2016). 
 
2.5.2. Cardiac function assessment 
To evaluate cardiac function imaging presents a crucial role. Combining cardiothoracic 
radiography and echocardiography with patients history, physical examination, blood and urine analysis 
and electrocardiogram, we are able to determine the presence of heart disease, as well as cause and 
severity (Pouchelon et al., 2015).  
Performing a cardiothoracic radiography, in at least two different orthogonal projections (e.g. 
laterolateral and ventrodorsal), we can evaluate changes to the hearts silhouette, pulmonary 
parenchymal pattern and vascular structures, assessing indicators for cardiac disease or CHF 
(Pouchelon et al., 2015). 
Cardiac morphology and function can be simply assessed by simple echocardiography, but 
using Doppler echocardiography (spectral Doppler, tissue Doppler, color flow Doppler), and recent 
AKI Grade Blood creatinine Clinical Description 
Grade I <1.6 mg/dl 
(<140 mol/l) 
Non Azotemic AKI:  
a. Documented AKI: (Historical, clinical, laboratory, or 
imaging evidence of AKI, clinical oliguria/anuria, volume 
responsiveness‡) and/or  
b. Progressive non azotemic increase in blood 
creatinine; ≥0.3 mg/dl (≥26.4 μmol/l) within 48 hours 
 c. Measured oliguria (<1ml/kg/hr) or anuria over 6 
hours 
Grade II 
1.7 – 2.5 mg/dl  
(141 – 220 µmol/l) 
Mild AKI: 
a. Documented AKI and static or progressive azotemia 
b. Progressive azotemic increase in blood creatinine; 
≥0.3 mg/dl ≥26.4 μmol/l) within 48 hours), or volume 
responsiveness‡  
c. Measured oliguria (<1ml/kg/hr) or anuria over 6 hours 
Grade III 
2.6 – 5.0 mg/dl  
(221 – 439µmol/l) 
 
Grade IV 
5.1 – 10.0 mg/dl 
(440 – 880 µmol/l) 
Moderate to Severe AKI: 
 a. Documented AKI and increasing severities of 
azotemia and functional RF 
Grade V 
>10.0 mg/dl  
(>880 µmol/l) 
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modalities as bi-dimensional speckle tracking, strain and strain rate, we can evaluate myocardial motion 
and blood flows velocity and direction with more detail (Chetboul & Tissier, 2012; Chetboul, 2010). 
Analyzing deviations on information collected through imaging methods, we can assess 
morbidity and expected mortality for heart disease in dogs and cats (Lord et al., 2011; Reynolds et al., 
2012) 
Another classic tool when evaluating cardiac function are cardiac biomarkers. NT-proBNP, 
BNP, NT-proANP and cTnI are the most commonly used biomarkers for detection of primary 
cardiovascular diseases, proving themselves very accurate (Boswood et al., 2008; Connolly, 2010; 
DeFrancesco et al., 2007; M. A. Oyama et al., 2013).  
Although being one of the most useful tools for cardiologists, their applicability to assess 
cardiac injury resultant from renal dysfunction hasn’t been proven yet. Despite lack of information, 
cardiac troponin is the only cardiac biomarker that might be applied in this cases, since its concentration 
is normally low in healthy dogs, and has shown to be increased in dogs and cats with cardiac disease 
(primary or secondary), indicating subclinical signs of cardiac injury, and helping to predict clinical 
outcome (Fonfara et al., 2010; Hezzell et al., 2012; Langhorn et al., 2013; M. a Oyama & Sisson, 2004; 
Pouchelon et al., 2015). It has, on other hand, shown increased serum or plasma concentration, as well 
as NT-proBNP and BNP, on dogs with AKI or CKI, but that showed normal cardiac function, because 
they go through renal excretion (Lalor et al., 2009; Miyagawa et al., 2013; Schmidt et al., 2009; Sharkey 
et al., 2009). 
As for NT-proBNP, BNP, and NT-proANP, although having given proves in the assessment of 
primary cardiac dysfunction, when evaluating cardiac injury resultant from kidney malfunction its 
applicability has yet to be fully studied, since they present continuous production by the myocardium, 
helping plasma volume, sodium excretion and vasomotor tone regulation in healthy and diseased 
patients (Potter et al., 2009), varying on “moment-to-moment basis” and according to disease stages, 
and showing, as well, variation in individuals and breeds in either healthy or diseased animals. which 
can lead to inaccurate conclusions (Kellihan et al. , 2009; Pouchelon et al., 2015; Sjöstrand et al., 2014).  
2.5.3. Blood pressure monitoring 
Blood pressure measurement is very important when monitoring animals with CRS (or CvRD). 
When assessing these values is essential to take on account the method throughout they’re obtained, 
and non-invasive methods are preferable (Pouchelon et al., 2015).   
SHT can be caused by heart or kidney dysfunction, or other pathologies, and can result in 
damage to both the heart and kidneys performance. This classifies SHT as an example of a mechanism 
that can lead to a disorder in the cardiorenal axis, being caused either of the three possible etiologies. 
A systolic pressure above 160 mmHg, is indicative of SHT (International Renal Interest Society, 2016), 
it can lead to permanent lesions in many different tissues, such as heart and vascular, as well as 
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increasing renal injury rate, decreased GFR, proteinuria and ultimately a higher mortality rate (Jacob et 
al., 2003).  
Systolic pressure under 90 mmHg is considered hypotension, and can cause cardiovascular 
and renal injury (Pouchelon et al., 2015). 
  
3. Therapeutics 
3.1. Therapeutic Challenge 
CRS presents a major therapeutic challenge. Although specific studies in the mater are 
lacking, it’s fairly well known empirically, that patients with cardiac insufficiency are prone to develop 
renal impairment with continuous cardiac treatment. Kidney failure develops in cardiac patients, either 
as a result to compensatory mechanisms to cardiac malfunction, either by chronic aggression to the 
kidneys caused by many of the drugs commonly used in cardiac patient’s treatments (Pouchelon et al., 
2015).  
When any animal presents with congestive signs of cardiac insufficiency, such as pulmonary 
edema, the main objective is to perform aggressive diuresis, as well as providing protein 
supplementation when showing cardiac caquexia (C. Atkins et al., 2009; Borgarelli & Haggstrom, 2010). 
But when it’s an animal with fully developed CRS, or CvRD, the same objective sustains, but the 
scenario has totally changed. This time the main goal resides, but with the additional premise of not 
compromising renal function furthermore and avoid the development of acute kidney failure (Pouchelon 
et al., 2015). 
The same principle applies conversely. In an animal, suffering from acute kidney failure, the 
main point is to lower uremic toxins concentration, usually performing aggressive fluid therapy. But in 
cases of CRS, or CvRD, where the animal also has cardiac insufficiency, aggressive fluid therapy will 
lead to congestive signs to appear (Pouchelon et al., 2015).  
Although it may be difficult, it is also crucial to carefully manage the therapeutics in patients 
with CRS, either in emergency situations as in chronic treatment, as it will directly reflect on the animal 
life expectancy (Pouchelon et al., 2015). 
3.2. Global vision – therapeutic strategies  
A global vision to the therapeutic strategies resides on trying to enhance one of the organs 
function to the most without causing further damage, or deterioration, to the other organ, which 
translates in constant monitoring to cardiac and renal function and also a constant reviewing to 
therapeutic dosages (Pouchelon et al., 2015). 
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In patients presenting CRS type 1 and 2, or CvRDH, there are three major points to consider: 
avoid causing short-term damage whilst providing CHF treatment, increase monitoring to renal function 
parameters and, ultimately, develop a therapeutic plan that preserves the kidney as much as possible 
(Tang & Mullens, 2010). 
In CRS types 3 and 4, or with CvRDK, the main therapy goal is to combine different uremic 
toxins excretion treatments, in order to minimize IV fluid intake necessary, reducing the patient’s chance 
to develop congestive signs (Pouchelon et al., 2015).  
3.3. Management  
3.3.1. Diuretics 
Diuretics are the first line option when it comes to control CHF. They are used to control 
pulmonary congestion in patients with volume overload, and maintaining hydrostatic balance (Krum et 
al., 2006). The most common diuretics used are furosemide and hydrochlorothiazide (C. E. Atkins & 
Häggström, 2012; C. Atkins et al., 2009; Goutal et al., 2010). Studies in humans show that loop diuretics, 
such as furosemide, are preferable to hydrochlorothiazide in patients with growing creatinine serum 
concentration, since the last one is majorly ineffective in patients with advanced states of RF (Attanasio 
et al., 2010; Fliser et al., 1994).  
Patients suffering from CRS tend to acquire resistance to diuretic effect, resulting in persistent 
pulmonary congestion, needing higher doses in order to achieve therapeutic concentrations in renal 
tubules, as kidney function decays (Boerrigter & Burnett, 2004). Diuretic therapy can cause pre-renal 
azotemia, decline of renal function and electrolyte balance. Therefore, the major goal when applying 
diuretic therapy, is to achieve optimal results at minimum dosage, reducing the total daily dosage of 
diuretics (Pouchelon et al., 2015).  
In order to minimize adverse effects to the kidney, excessive diuresis, maintain a correct 
electrolyte balance and renal perfusion, it’s advised to keep patients on supplementary IV fluids low on 
sodium during aggressive diuretic therapy (Pouchelon et al., 2015). 
Table 3 - Diuretics dosage for dogs and cats. Adapted from (“Merck Vet Manual,” 2016) 
Drug Treatment Administration Dosage for dogs Dosage for cats 
Furosemide  
Life-
threatening 
cardiogenic 
pulmonary 
edema 
IV, IM or SC 
2-4 mg/kg 
Every 1-6 hour  
0.5-2 mg/kg 
Every 1-8 hour 
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Constant rate 
infusion 
IV 0.25-1 mg/kg/hr 0.25-0.6 mg/kg/hr 
 
Long-term 
management  
PO  
Start – 2 mg/kg 
BID 
Range – 1-5 mg/kg 
BID/TID 
Start – 1 mg/kg SID 
Range – 1-2 mg/kg 
SID/BID  
Up to 4-6 mg/kg daily 
Hydrochlorothiazide  Monotherapy  PO 2-4 mg/kg BID 0.5-2 mg/kg SID/BID 
 
Combined 
with 
furosemide 
PO  
Start: 2 mg/kg BID 
Furosemide 
dosage lowers to 
25-50%  
 
Torsemide 
Long-term 
management 
PO  
0.25-0.4 mg/kg 
SID/BID 
 
 
3.3.2. Angiotensin converting enzyme inhibitors  
ACEI are one of the most commonly used drugs, when treating patients with heart failure. 
ACEI, such as benazepril, enalapril, imidapril and ramipril, act as vasodilators, reversing the side effects 
of chronic activation of the RAAS (excessive fluid retention) that occur in cardiopathic dogs (Guglielmini, 
2003). Since they reduce blood pressure, they are considered a “kidney ally” in cardiac patient’s therapy.  
Nonetheless, in animals being treated for acute CHF, some veterinarians prefer to stop 
administration of ACEI, since, associated to diuretic use, it can cause an accentuated volume depletion, 
which might lead to ACEI-induced kidney injury (C. Atkins et al., 2009). This renal injury is heightened 
in patients that already suffer from CKD (Liu et al., 2012). Although occurrence of hyperkalemia in 
animals receiving ACEI is relatively rare, it should be monitored, as they cause potassium retention (C. 
Atkins et al., 2009; Fleming, 2006). When treating acute CHF, if it’s chosen withheld ACEI therapy during 
critical phase it’s recommended to reintroduce them, after the patient shows no sign of congestion. One 
might also administer the lower dosage in the recommended range, while evaluating the patients 
hydration status and renal function, before making further dosage adjustments (Pouchelon et al., 2015). 
In cases where the animals present severe volume depletion, renal azotemia or uremia after treatment, 
requiring supplementary fluids, it’s recommended to provide low sodium and potassium fluids. In cases 
of renal dysfunction it’s crucial to monitor serum concentrations of potassium, as well as when combining 
ACEI with spironolactone (Pouchelon et al., 2015), which will be further addressed.  
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Table 4 - ACEI dosage for dogs and cats. Adapted from (“Merck Vet Manual,” 2016) 
Drug Treatment Administration Dosage for dogs Dosage for cats 
Enalapril or 
Benazepril   
CHF PO 
0.25-0.5 mg/kg 
SID/BID  
0.25-0.5 mg/kg BID 
0.5 mg/kg SID 
 SHT PO  
0.25-0.5 mg/kg 
SID/BID 
0.25-0.5 mg/kg BID 
0.5 mg/kg SID 
 
Captopril  
CHF PO 0.5-2 mg/kg TID 0.5-2 mg/kg TID 
 
Lisinopril CHF PO  0.5 mg/kg SID/BID 0.5 mg/kg SID/BID 
 
3.3.3. Beta-blockers 
Beta-blockers, such as atenolol, are commonly used in animals with left atrial enlargement, 
and can also be used in order to reduce arrhythmias, infundibular gradient, dynamic left ventricular 
outflow gradient, syncopal events and to prevent sudden death (Bonagura & Twedt, 2009) . Upon finding 
alterations of left atrium, either on a primary evaluation or on a control echocardiography, beta-blockers 
are usually prescribed in order to slow disease progression. Its use it’s not recommended when signs 
of CHF are present, but it’s many times recommended to add them to the medication regimen, in order 
to protect myocardium from deterioration (C. Atkins et al., 2009). 
Acting by preventing endogenous catecholamines on beta-receptors, its benefit to the patient 
in humans it’s often compared to ACEI (Liu et al., 2012). Some medical studies associate the use of a 
beta-blocker, bisoprolol, a highly selective β1-adrenoceptor antagonist, to a good outcome in patients 
with HF with simultaneous renal dysfunction (Castagno et al., 2010; “The Cardiac Insufficiency 
Bisoprolol Study II (CIBIS-II): a randomised trial,” 1999).  
Table 5 - Beta-blockers dosage for dogs and cats. Adapted from (“Merck Vet Manual,” 2016) 
Drug Treatment Administration Dosage for dogs Dosage for cats 
Atenolol    CHF PO 0.2-1 mg/kg BID  
1-2.5 mg/kg BID 
6.25-12.5 mg/cat 
BID 
13 
 
Sotalol  CHF PO  1-2.5 mg/kg BID 1-2.5 mg/kg BID 
 
3.3.4. Angiotensin receptor blockers  
Presenting similar effects to ACEI, angiotensin receptor blockers are used to prevent the 
vasoconstriction, SNS stimulation, sodium reabsorption and, as they prevent angiotensin to bind to its 
receptor, aldosterone secretion and renin synthesis (Siragy, 2000).  
Angiotensin receptor blockers, such as temilsartan, in the same way as ACEI, act as “kidney 
protectors” in cases of heart failure, as they have shown to be able to reduce proteinuria in studies 
conducted in humans, proving themselves as a valuable alternative to ACEI, but studies in dogs are yet 
to be considered conclusive (Bugbee et al., 2014) 
Table 6 - Angiotensin receptor blockers dosage for dogs and cats. Adapted from (“Merck Vet Manual,” 
2016) 
Drug Treatment Administration Dosage for dogs Dosage for cats 
Temilsartan     CKF PO 1 mg/kg BID  1 mg/kg SID 
 
3.3.5. Mineralocorticoid receptor antagonists  
Used to prevent hypertension, mineralocorticoid receptor antagonists as spironolactone, play 
an important in CHF management therapy (Bonagura & Twedt, 2009). They also play an important role 
in cardiac remodeling, as for studies in mice show that by treating patients with cardiac enlargement in 
early stages of disease with combined spironolactone with lisinopril, will not only slow disease 
progression as it will in fact cause improvement to the patients early condition (Rafael-Fortney et al., 
2011). 
 When using in patients that developed CRS (or CvRDH), it’s advised to play a close watch if 
patient presents low GFR, as it presents risk of developing hyperkalemia (Pouchelon et al., 2015).  
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Table 7 - Mineralocorticoid receptor antagonist dosage for dogs and cats. Adapted from (“Merck Vet 
Manual,” 2016) 
Drug Treatment Administration Dosage for dogs Dosage for cats 
Spironolactone      CHF PO 
1-2 mg/kg BID 
2 mg/kg SID  
1-2 mg/kg SID/BID 
 
3.3.6. Uremic toxins accumulation treatment 
In order to eliminate uremic toxins that accumulate in the organism due to kidney malfunction, 
as well as to prevent side effects from its accumulation there are two main therapeutic strategies. 
 The first one is to reduce the concentration of protein bound uremic toxins (Vanholder et al., 
2008). We can achieve this by two different means: in humans dialysis treatment with increased 
frequency, prolonged treatment time or using higher permeability membranes can be useful in uremic 
toxins removal (Eloot et al., 2008; Fagugli et al., 2002; Mucsi et al., 1998; Vanholder et al., 2008); in 
veterinary is by using activated charcoal absorbent, as AST-120. In human studies it has been proven 
to successfully absorb uremic toxins, linked to accelerated renal dysfunction, and also to reduce 
circulating levels of uremic toxins, serum creatinine and proteinuria in animals presenting CKD 
(Lekawanvijit et al., 2012; Schulman et al., 2006).  
The second option to control uremic toxins accumulation is to control its toxicity, by means of 
therapeutic strategies, such as ACE-inhibitors, beta-blockers, angiotensin receptor blockers and others 
(Vanholder et al., 2008).   
3.4. Prognosis 
Scientific data regarding the prognosis of dogs and cats with CRS is not available, but empiric 
data collected by veterinarian specialists seems to agree with the studies in human medicine that show 
poor prognosis in patients with concomitant cardiac and renal disease (Nodari & Palazzuoli, 2011). 
These studies associate this poor outcome mainly with renal impairment, because when it is associated 
to heart failure, it leads to a cascade of events that ultimately cause fluid retention and decompensation 
of the cardiac status. These studies also implicate that most of the drugs used to control CHF, as 
diuretics and vasodilators, can also be responsible, since they ultimately cause reduction in plasmatic 
volume, renal perfusion redistribution with cortical vasoconstriction, decrease in preload with increase 
in venous congestion, and further neurohormonal activation, which all further impair renal function, to a 
point when current therapies fail to improve (Nodari & Palazzuoli, 2011). 
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4. Future perspectives 
With CRS being a relatively new area of interest in veterinary medicine, there isn’t much 
knowledge on the subject so far that can be successfully applied in small animals’ therapy.  
Future perspectives for CRS, or CvRD, should go through further investigation, in order to 
overcome this lack of current knowledge. Besides improving our knowledge on the pathology itself, it is 
also very important to elaborate new and/or better therapeutic plans, that overcome certain flaws in 
current ones. On that ground, it would be of great interest to study the applicability in dogs and cats of 
certain new therapies that are already being used in humans, such as erythropoietin in anemic in CKD 
and CHF and also the use of inotropes to improve renal function.  
Studies in humans, have shown that patients with HF that also have anemia (common in HF 
and CKD), would have higher mortality rates than those with normal levels of red blood cells and that 
patients with CKD would present lower concentrations of erythropoietin (Bock & Gottlieb, 2010a). 
Although anemia should cause an erythropoietin rise, in patients with CRS, erythropoietin levels were 
also found to be low, which results in further damage to the kidneys, resulting from oxidative stress. This 
will further affect the kidneys’ ability to produce erythropoietin, aggravating the anemia, leading to a 
higher mortality rate (Bock & Gottlieb, 2010a).  
Despite the fact that the studies already conducted in humans haven’t shown direct clinical 
benefit of using such drugs as dopamine (Kellum & M Decker, 2001), positive inotropes continue to be 
used in patients with worsening renal function secondary to decreased blood flow, because they are 
believed to improve renal blood flow, although their use is not recommended in cases of acute 
decompensated heart failure (Bock & Gottlieb, 2010a). Much like in human medicine, new drugs are 
developed every year on the veterinary field, and it would be interesting to study their applicability in 
dogs and cats.  
Future studies on the matter should also address more specific and more sensitive means of 
diagnosis, as specific biomarkers. Biomarkers represent a potentially useful tool since they can be used 
as: a diagnostic test in the identification of patients with the disease, as well as staging or classifying of 
the extent of the disease; an indicator of disease prognosis and monitoring of clinical response to an 
intervention (Biomarkers Definitions Working Group, 2001). 
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5. Final intakes  
Cardiorenal syndrome, or cardiovascular-renal axis disorder, is becoming an increasingly 
more common and recognized pathology in veterinary practice. With the advances occurred in internal 
medicine in the field of cardiology, we are able to provide proper treatment to animals suffering from 
cardiac disease, resulting in an increased life expectancy for such patients. Having cardiac disease 
controlled with therapy, the problem that presents itself is how will the therapeutic plan affect other 
organs. CRS, or CvRD, is the most common complication in these cases, affecting a larger percentage 
of both dogs and cats.  
Despite having a great importance and effect on the animal life expectancy, it wasn’t only until 
recently that this problem gained attention, not only in veterinary but also in human medicine. Because 
of this, there is serious lack of information regarding this subject. Not only we do not know the exact 
pathophysiological mechanism behind it, but we also don’t have specific epidemiologic data, nor specific 
studies that back up the information collected by veterinarians (both cardiologists and nephrologists), 
making it mostly empirical. Adding to this, most of the information that already exists on the subject has 
only been studied in humans. 
Therefore, by modeling after already existent medical studies, it would be interesting to 
develop further knowledge on certain important topics in this subject, such as the role of erythropoietin 
in anemia associated with CKD and CHF.  
Regarding diagnosis, there is also interest on further developing our knowledge, by 
investigating new biomarkers specific to renal and cardiac injury, as they can be helpful on disease 
staging and also to evaluate responses to certain therapies, which could prove to be useful in 
therapeutics management. 
On a therapeutic perspective, until this point, the options available to animals with CRS, or 
CvRD, haven’t been developed much further than dosage control and patient monitoring. CRS 
therapeutics in veterinary patients address cardiac function improvement while trying to minimize 
damage caused to the kidneys, and therapeutic plans that aim to actually improve renal function are 
lacking. For that reason, new studies are required, in order to gain a deeper knowledge on this 
syndrome, so we can act on more specific therapeutic targets, with randomized studies that can help 
appraise prognosis in different therapeutic plans  
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